The clinical uroselectivity of alfuzosin is not significantly affected by the age of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia

Abstract

The clinical uroselectivity of alfuzosin is not signi®cantly affected by the age of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia i.e. <56, 56±65, 66±75 and >75 years. All groups of patients showed a mean IPSS decrease of 11±12 (55.8±65.4% from baseline) at the end of the study, while the QoL decreased by 2±3 points (55.6±63.6% from baseline). There were no relevant effects of age on the ef®cacy of the treatment. Moreover, alfuzosin was well tolerated independently of the age of the patient; 1.2% of the patients enrolled withdrew because of adverse events. The qualitative distribution of vasodilatory/nonvasodilatory adverse events was similar in all age groups. The incidence of asymptomatic orthostatic hypotension was low (0.58%) and not affected by the age of the patients. Conclusion This study con®rms that the clinical uroselectivity of SR-alfuzosin, already described in randomized controlled studies, is not signi®cantly affected in clinical practice by the age of the patients. This is considered particularly relevant to the characteristics of patients with BPH, as they are mostly elderly men.

Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily

“…A significant mean improvement from baseline of 11 to 12 points in the IPSS was demonstrated for all age groups after 2 months of treatment with alfuzosin, with both irritative and obstructive LUTS improving significantly when compared with baseline values. In addition, significant mean improvements in the IPSS bother score of 2–3 points were shown for all age groups after 2 months of treatment with alfuzosin when compared with baseline values (Sanchez-Chapado et al 2000). The results of this study in a clinical-practice setting are in agreement with those of clinical trials indicating that age does not affect the clinical efficacy of alfuzosin 10 mg.…”

“…In an open-label study of the effect of age on the efficacy of treatment with alfuzosin 10 mg/day, 4018 men with LUTS/BPH from general medical practices were stratified into 4 age groups: <56 years, 56 to 65 years, 66 to 75 years, and <75 years (Sanchez-Chapado et al 2000). A significant mean improvement from baseline of 11 to 12 points in the IPSS was demonstrated for all age groups after 2 months of treatment with alfuzosin, with both irritative and obstructive LUTS improving significantly when compared with baseline values.…”

Selecting therapy for maintaining sexual function in patients with benign prostatic hyperplasia

“…prazosin, terazosin and doxazosin), tamsulosin and alfuzosin are associated with a low incidence of postural symptoms, similar to that seen with placebo [26,27,52]. Although alfuzosin shows no subtype specificity on in vitro tests, it does appear to be clinically uroselective [44,53–56].…”

Pharmacokinetics and Safety of a Single Oral Dose of Once‐Daily Alfuzosin, 10 mg, in Male Subjects with Mild to Severe Renal Impairment

“…8 It has a favorable tolerability profile, particularly with regard to the cardiovascular system. [9][10][11][12][13] Alfuzosin is extensively metabolized by the liver, and only 11% of the parent compound is excreted unchanged in the urine. 7 Previously, alfuzosin has been available in two bioequivalent formulations: as an immediate-release tablet, 2.5 mg three times daily (tid), and a slow-release tablet, 5 mg twice daily (bid).…”

“…The prevalence of BPH rises from 138 per 1000 men aged 40 to 49 years to 430 per 1000 men aged 60 to 69 years. 20 By the age of 80 years, around 80% of men are affected, 21 and it is estimated that nearly half of these patients will develop moderate (International Prostate Symptom Score [I-PSS] of [8][9][10][11][12][13][14][15][16][17][18][19] to severe (I-PSS ≥ 20) urinary symptoms that will interfere with normal daily activities and impair quality of life. 22,23 At present, the number of individuals older than age 65 years is increasing faster than any other age group.…”